Search Results 2041-2050 of 21639 for platelets

1. Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL - Mayo Clinic

   Platelets ≥ 75,000/µL. Total or Direct bilirubin ≤ 2 mg/dL. AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN. Creatinine ≤ 1.5 x institutional ULN or ...

2. A Study to Assess Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

   Platelets < 75.0 x109/L 6. Albuminemia < 3.0 g/dL. Suspected or documented infectious enterocolitis within two weeks prior to Screening visit. Any prior ...

3. Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer - Mayo Clinic

   Platelet (PLT) ≥ 100,000; Hemoglobin (HgB) > 9.0 g/dL; Total bilirubin ≤ institutional upper limit of normal (ULN); Serum glutamic oxaloacetic transaminase ...

4. Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma - Mayo Clinic

   Platelet count ≥ 100,000/mm³; Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal; Alkaline phosphatase ≤ 3 times ULN (5 ...

5. Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery - Mayo Clinic

   Platelet count ≥100,000/µL; Total Bilirubin ≤ 2.0 x ULN; UPC ratio <1 or Urine protein ≤ 1+; Calculated creatinine clearance ≥ 45 ml/min; SGOT/SGPT(AST/ALT) ...

6. A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis - Mayo Clinic

   Subjects with a risk of clinically significant bleeding events, including those with coagulation or platelet disorders at screening. Subjects with a history ...

7. Polyphenon E in Treating Patients with High-Risk of Colorectal Cancer - Mayo Clinic

   Platelet count ≥ 100,000/ul; White blood cells (WBC) ≥ 3,000/ul; Alanine aminotransferase (ALT) within institutional limits of normal; Alkaline phosphatase ...

8. Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery - Mayo Clinic

   Platelet Count > 100,000/mm^3; Total Bilirubin < 1.5 x upper limits of normal (ULN); Creatinine < 1.5 x ULN; Serum alanine transaminase (ALT) < 2.5 x ULN.

9. A Study of Nab-Paclitaxel as Maintenance Treatment After Cisplatin-Based Chemotherapy and Surgery for Patients with High-Risk Bladder Cancer - Mayo Clinic

   Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 mg/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ...

10. The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) - Mayo Clinic

    ... platelet transfusions. The overall response rate was 40 %, including hematologic improvement in 28 % of patients and RBC transfusion independence sustained ...